DATA

Our exclusive database of multinational medical companies and their subsidiaries

The world’s leading medical companies operate an average of 114.1 subsidiaries each. We reveal the global hotspots for these operations.

Powered by 

Medical multinationals are far less likely to establish subsidiaries in Asia-Pacific than the average multinational company according to analysis of GlobalData's exclusively compiled subsidiary database.

Companies establish subsidiaries for a variety of reasons: they can allow them to expand into profitable new markets, to increase revenue, and to diversify their holdings to better manage risk. As a vital component to a company’s expansion plans, the establishment of a subsidiary can offer insight into investment trends, with our database allowing you to see these investment patterns on a wider, sector level.

GlobalData’s multinational company database - which can be viewed in full on our sister site Investment Monitor contains information for 2,188 of the world’s top multinational companies (MNCs) by revenue. Of these MNCs, 72 are in the medical industry, representing 3.3% of the companies in our database.

These medical companies are less likely than average to establish subsidiaries in Asia-Pacific (19.6% vs 21.4%) and are more likely to establish them in North America (29.3% vs 27.8%).

Overall, the 72 medical MNCs in our database operate 8,218 subsidiaries. This comes to an average of 114.1 subsidiaries per company, compared to an average of 99 for the entire database of 2,188 companies. It should be noted, however, that the number of subsidiaries is by no means evenly distributed within the sector. The most common number of subsidiaries for an MNC in the sector (the mode) is 39, while the median comes in at 58.5, indicating that the simple average is skewed heavily by the bigger parent companies.

US-based Thermo Fisher Scientific Inc has the largest number of subsidiaries among the medical sector MNCs within our database with 1,025. This means it ranks in eighth place across our entire database when measured by the total number of subsidiaries.

Where has Thermo Fisher Scientific Inc established subsidiaries?

Thermo Fisher Scientific Inc’s subsidiaries are distributed across the world with 42.7% of the total located in Western Europe, the highest for any region. Some 342 of Thermo Fisher Scientific Inc's subsidiaries are located in its home country of the US, while the UK was the second most popular destination with 128.

After Thermo Fisher Scientific Inc, Abbott Laboratories had the second largest number of subsidiaries within the medical industry MNCs in the database with 581, while Johnson & Johnson was third with 514 and DaVita Inc was fourth with 457.

Where has Eurofins Scientific SE established subsidiaries?

Overall, 2,427 of the subsidiaries owned by the medical MNCs in the database were located in the same country as the parent company was headquartered. This meant that MNCs in the sector were less likely than average to have a preference for domestic subsidiaries at 29.5%, with the figure for the entire database standing at 45.7%.

Methodology

GlobalData has compiled a list of top MNCs based on revenue. Any top companies that did not have a subsidiary were removed from the list. The latest company annual reports (2019 and 2020, where available) and websites were analysed for a total of 2,188 companies. For a subsidiary to be included, the parent company had to have a majority ownership/control in the subsidiary. Affiliates, associates, joint operations and joint ventures were included as long as the ownership criteria was met. Subsidiary information was captured at a country level. Country names were standardised. In total, 216,898 subsidiaries were captured.

Go to article: Home | Weathering the stormGo to article: In this issueGo to article: ContentsGo to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: Pulse Technologies Company InsightGo to article: Pulse TechnologiesGo to article: BriefingGo to article: Industry newsGo to article: The medical industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: fusetecGo to article: GS SwissGo to article: Proportion AirGo to article: CommentGo to article: In vitro fertilisation devices market set for steady growth post-Covid-19Go to article: Smart insulin pens gain ground in the insulin delivery marketGo to article: Data protection must be a healthcare priority to avoid breachesGo to article: ProByLas Company Insight Go to article: ProByLas Go to article: Lenzing Plastics Company InsightGo to article: Lenzing PlasticsGo to article: In DepthGo to article: The smart toilet: a pipe’s-eye view of gastrointestinal healthGo to article: Will CMS reimburse the cost of innovation in medical devices?Go to article: Sharief Taraman: using AI to fight disparities in medicineGo to article: The power problem: how power cuts are threatening home careGo to article: Sensors and sensitivityGo to article: How should we be regulating LDTs?Go to article: ElectroCraft Company InsightGo to article: ElectroCraftGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: In DataGo to article: Data: medical subsidiaries Go to article: The medical industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: Apple RubberGo to article: AccumoldGo to article: EventsGo to article: Next Issue